Physician profile
Rachel Brinkerhoff
NPI 1598462152
$10,140.80
in general payments reported to CMS, 2019-2025
43 companies · $3,104 in 2025
The $3,104 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,777 · 2024: $4,260 · 2025: $3,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,937 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,937.39 |
| Education | $203.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,447.23 | 2023-2025 | |
| Pfizer INC. | $878.24 | 2023-2025 | |
| Lilly USA, LLC | $716.18 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Jazz Pharmaceuticals INC. | $597.37 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $565.67 | 2023-2025 | |
| Sk Life Science, INC. | $472.02 | 2023-2025 | Xcopri |
| Lundbeck LLC | $408.69 | 2023-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $398.76 | 2023-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $339.02 | 2023-2025 | Nayzilam, Rystiggo, Zilbrysq |
| Otsuka America Pharmaceutical, INC. | $329.01 | 2023-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $321.37 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $318.44 | 2023-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $241.61 | 2023-2025 | Hyqvia, Trintellix |
| Mallinckrodt Hospital Products INC. | $233.85 | 2023-2025 | Acthar |
| Axsome Therapeutics, INC. | $220.23 | 2023-2025 | Sunosi, Symbravo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $215.58 | 2023-2025 | Nuplazid |
| Genentech USA, INC. | $192.01 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $191.15 | 2024-2025 | |
| Acorda Therapeutics, INC | $186.90 | 2023-2024 | Inbrija |
| Mdd US Operations, LLC | $165.01 | 2024-2025 | Gocovri |
| Eisai INC. | $161.98 | 2024-2025 | |
| Grifols USA, LLC | $157.72 | 2023-2025 | Gamunex-C |
| Biogen, INC. | $149.35 | 2023-2025 | Vumerity, Skyclarys, Tysabri |
| Teva Pharmaceuticals USA, INC. | $116.98 | 2023-2024 | Austedo Xr, Ajovy |
| Csl Behring | $111.06 | 2024-2025 | Hizentra |
| Merz Pharmaceuticals, LLC | $99.30 | 2023-2024 | Xeomin |
| Inspire Medical Systems, INC. | $87.23 | 2025 | Inspire |
| Neurelis, INC. | $86.28 | 2023-2025 | Valtoco |
| Merck Sharp & Dohme LLC | $85.38 | 2023 | Belsomra, Welireg |
| Averitas Pharma INC. | $83.44 | 2024-2025 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $82.83 | 2023-2024 | Fycompa, Firdapse |
| Medtronic, INC. | $77.03 | 2024-2025 | Percept PC Brainsense, Activa PC |
| Amneal Pharmaceuticals LLC | $68.93 | 2024-2025 | Crexont |
| Alnylam Pharmaceuticals INC. | $56.96 | 2023-2025 | Amvuttra, Givlaari |
| Xeris Pharmaceuticals, INC. | $55.73 | 2024 | Keveyis |
| Avadel Cns Pharmaceuticals, LLC | $46.46 | 2024-2025 | Lumryz |
| Amgen INC. | $41.05 | 2024-2025 | Uplizna |
| Tanabe Pharma America, INC. | $35.61 | 2024-2025 | Radicava |
| Ge Healthcare | $26.61 | 2024 | |
| Janssen Biotech, INC. | $20.57 | 2025 | |
| Cala Health, INC. | $19.74 | 2025 | Cala Kiq |
| Astrazeneca Pharmaceuticals LP | $19.40 | 2025 | Wainua |
| Horizon Therapeutics Plc | $12.82 | 2023 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Brinkerhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.